Oncology

Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.

Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-...

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discus...

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

Tran Ho, DO, FSSO, FACS, discussed how she found her passion in breast surgical oncology and how her mentors helped her achieve success.

Oncology Decoded provides the current management of metastatic bladder cancer, recent advancements in systemic therapy, patient selection, and AE miti...

Patients with extensive-stage small cell lung cancer experienced a median PFS and OS of 4.5 months and 7.2 months, respectively, with anlotinib plus i...

Panelists discuss how the step-up dosing strategy for talquetamab involves graduated dose escalation from 0.01 to 0.06 mg/kg before reaching therapeut...

“It’s a treatment for those patients who don’t have any other effective treatments available,” said Muhammad Umair Mushtaq, MD, on lifileucel in melan...

Panelists discuss how patients with relapsed/refractory (R/R) multiple myeloma experience the challenging process of confirming disease recurrence thr...